USPTO Examiner MOSS NATALIE M - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18415270METHOD OF TREATING OR REDUCING EFPJanuary 2024November 2025Abandon2220NoNo
18518528COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOMENovember 2023May 2025Abandon1710NoNo
18494126METHODS OF TREATMENT FOR FUNCTIONAL DECLINE IN HIPPOCAMPUS, FOR IMPROVING RECOGNITION MEMORY ACCURACY, AND FOR IMPROVING HIPPOCAMPAL NEURONAL FUNCTIONOctober 2023November 2025Abandon2520NoNo
18465214DIFFERENTIATION AND ENRICHMENT OF ISLET-LIKE CELLS FROM HUMAN PLURIPOTENT STEM CELLSSeptember 2023December 2025Abandon2720NoNo
18301782Multilayered Vascular TubesApril 2023October 2025Abandon3030NoNo
18185049HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAMEMarch 2023January 2025Abandon2211NoNo
17918699Methods and Compositions For Reducing Joint Inflammation Using Mesenchymal Stem CellsOctober 2022February 2026Abandon4010NoNo
17929364METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL LINE FROM MESENCHYMAL STEM CELLS, AND CELL LINE OBTAINED THEREBYSeptember 2022November 2025Abandon3831NoNo
17822946IN VITRO DRUG METABOLISM REAGENT AND USES THEREOFAugust 2022February 2026Abandon4111NoNo
17627905COMPOSITION FOR REGENERATING NUCLEUS PULPOSUSJune 2022November 2025Abandon4610NoNo
17638026METHOD FOR PRODUCING VASCULAR ENDOTHELIAL STEM CELLFebruary 2022October 2025Abandon4310NoNo
17559953DRUG COCKTAIL ANALYSES USING MICROSCALE VORTEX-ASSISTED ELECTROPORATIONDecember 2021September 2024Abandon3220NoNo
17556337PHARMACEUTICAL PREPARATION COMPRISING SUPERNATANT OF BLOOD MONONUCLEAR CELL CULTURE AND METHOD OF USEDecember 2021September 2025Abandon4510NoNo
17618322MEANS FOR USE IN PREPARATION OF HYDROGEL BASED ON HYDROXYPHENYL DERIVATIVE OF HYALURONAN, METHOD OF HYDROGEL PREPARATION AND USE THEREOFDecember 2021September 2025Abandon4601NoNo
17539767METHODS FOR TREATING AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMSDecember 2021November 2025Abandon4810NoNo
17522297INJECTABLE, PORE-FORMING HYDROGELS FOR MATERIALS-BASED CELL THERAPIESNovember 2021July 2025Abandon4401NoNo
17519186MONITORING AND MODIFYING THE MICROBIOME IN PATIENTS WITH RECTOVAGINAL FISTULANovember 2021July 2024Abandon3320NoNo
17514619THREE-LAYER STRUCTURE INCLUDING EXTRA-CELLULAR MATRIX, SHEET-SHAPED CELL CULTURE, AND BIODEGRADABLE GELOctober 2021January 2026Abandon5121NoNo
17606750PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLSOctober 2021April 2025Abandon4201NoNo
17496734COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASEOctober 2021April 2024Abandon3020NoNo
17441714REDOX ENZYMES IN ANIMAL FEED COMPOSITIONSSeptember 2021February 2025Abandon4111NoNo
17465382Methods and Systems For Saccharification of BiomassSeptember 2021May 2023Abandon2110NoNo
17430634Cell-Free Compositions for ATP Regeneration and Uses ThereofAugust 2021January 2026Abandon5331NoNo
17379321METHOD OF PURIFYING ACTIVE SOLUBLE MATRIX METALLOPROTEINASESJuly 2021November 2023Abandon2811NoNo
17420732ENHANCING EPITHELIAL OR ENDOTHELIAL BARRIER FUNCTIONJuly 2021July 2025Abandon4841NoNo
17344414ENZYME COMPOSITIONS AND USE THEREOF FOR WOUND HEALINGJune 2021May 2023Abandon2310NoNo
17302747SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN ANIMALSMay 2021November 2025Abandon5431NoYes
17291081METHOD FOR MANUFACTURING HIGHLY PURIFIED LACTOFERRIN AND LACTOPEROXIDASE FROM MILK, COLOSTRUM AND ACID OR SWEET WHEYMay 2021May 2025Abandon4931NoNo
17287670USE OF GLUCOSYLCERAMIDE SYNTHASE GENE-DEFICIENT T CELL AND THERAPEUTIC UTILIZATION THEREOFApril 2021September 2024Abandon4101NoNo
17236736METHODS OF GANGLIOSIDE PRODUCTIONApril 2021May 2023Abandon2501NoNo
17223123MEDICAL-GRADE HONEY FOR GROWTH ENHANCEMENT OF INFANTSApril 2021May 2023Abandon2510NoNo
17281535EXTRACELLULAR VESICLES FOR REPLACEMENT OF UREA CYCLE PROTEINS & NUCLEIC ACIDSMarch 2021August 2024Abandon4101NoNo
17212528METHOD FOR CONTINUOUS SECOND-GENERATION ETHANOL PRODUCTION IN SIMULTANEOUS SACCHARIFICATION AND CO-FERMENTATION PROCESSMarch 2021November 2024Abandon4411NoNo
17274601ANIMAL FEED COMPOSITION AND USE THEREOFMarch 2021March 2024Abandon3611NoNo
17269235ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE, METHODS, USES, APPARATUSES AND SYSTEMS ASSOCIATED THEREWITHFebruary 2021August 2024Abandon4221NoNo
17269238ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE ON DONOR ORGANS, METHODS AND USES ASSOCIATED THEREWITHFebruary 2021July 2024Abandon4121YesNo
17163065Method of Treating a Disorder of Cognitive Performance or MemoryJanuary 2021May 2024Abandon3920NoYes
17152543SYSTEMS AND METHODS FOR GROWING CELLS IN VITROJanuary 2021October 2025Abandon5771YesNo
17259898MODEL FOR IN-VITRO SIMULATION OF THE BEHAVIOUR OF DYSFUNCTIONAL VESSELSJanuary 2021November 2024Abandon4601NoNo
17142932In vitro Transcription-Translation Metabolic Networks to Measure Quantity or Activity of EnzymesJanuary 2021June 2025Abandon5331NoNo
17254029USE OF AN EXTRACELLULAR MATRIX (ECM) HYDROGEL AS AN ESOPHAGEAL SUBMUCOSAL FLUID CUSHIONDecember 2020July 2022Abandon1910NoNo
17120042CANNABINOID ENRICHED COMPOSITION AND METHOD OF USINGDecember 2020October 2023Abandon3411NoNo
16953002INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOFNovember 2020February 2026Abandon6041YesNo
17089469COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOMENovember 2020January 2024Abandon3921NoNo
17075486SSCF PROCESS FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASS AND 2G RESIDUAL BIOMASSOctober 2020July 2024Abandon4420NoNo
17045110GENE THERAPY FOR OXIDATIVE STRESSOctober 2020February 2024Abandon4001NoNo
17043885USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMS FOR TREATMENT OF NEURODEGENERATIVE DISORDERSSeptember 2020April 2024Abandon4210NoNo
17012531COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTHSeptember 2020August 2025Abandon5931NoYes
16989701HOLDERS FOR BIOREACTOR SENSORS, BIOREACTORS HAVING SUCH HOLDERS, AND METHODS CULTURING BIOLOGICAL MATERIALAugust 2020April 2023Abandon3201NoNo
16937451METHOD FOR PRODUCING ANTIGEN-SPECIFIC T CELLSJuly 2020February 2025Abandon5431NoNo
16935639TRITURATION DEVICES FOR TISSUE DISAGGREGATIONJuly 2020May 2023Abandon3301NoNo
16892156PLURIPOTENT STEM CELL-DERIVED MACROPHAGE CAPABLE OF TARGETING TUMOR CELLS AND PREPARATION METHOD THEREOFJune 2020October 2024Abandon5221NoNo
15929579BACTERIAL STRAIN COMPOSITIONS AND METHODS OF USING SAMEMay 2020July 2023Abandon3811NoNo
16757181Anaerobic Cell-Free Systems and Environments and Methods for Making and Using SameApril 2020July 2025Abandon6021NoNo
16648349RIBOFLAVINASE ENZYMES AND THEIR USE TO PREVENT OFF FLAVOR IN BREWINGMarch 2020October 2024Abandon5521NoNo
16643713AN AGENT, A DEVICE AND A BLOOD-CIRCULATION SYSTEM FOR TREATING LYSOSOMAL STORAGE DISEASES, AND A METHOD FOR TREATING LYSOSOMAL STORAGE DISEASESMarch 2020August 2025Abandon6061YesNo
16806404Dosing Regimens For The Treatment Of Fabry DiseaseMarch 2020October 2023Abandon4320NoNo
16640807TRANSPOSON SYSTEM AND METHODS OF USEFebruary 2020November 2023Abandon4420NoNo
16639624Methods for Antimicrobial Susceptibility TestingFebruary 2020October 2023Abandon4430NoNo
16635142CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR TREATMENT AND PREVENTION OF CANCERJanuary 2020May 2024Abandon5131NoNo
16751708Stable Bioactive Substances and Methods of MakingJanuary 2020April 2023Abandon3811NoNo
16710545BIOLOGICAL COMPOSITION FOR DEGRADING PLANT PESTICIDE RESIDUES AND THE APPLICATION THEREOFDecember 2019January 2024Abandon4940NoNo
16684142METHOD FOR TREATMENT OF INFERTILITY, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFERTILITY AND METHOD FOR PRODUCING THE SAMENovember 2019March 2023Abandon4040YesNo
16606795METHOD FOR PREPARING CANCER STEMNESS CELL LINE THROUGH METABOLIC STRESS, AND CANCER CELL PREPARED THROUGH SAMEOctober 2019December 2025Abandon6061NoNo
16603927METHODS FOR IDENTIFYING THE HEALTH STATE OF HYPOPHOSPHATASIA (HPP) PATIENTSOctober 2019April 2025Abandon6031NoNo
16540934Multilayered Vascular TubesAugust 2019December 2023Abandon5240NoNo
16532801Method of Assessing Liver Triglyceride Levels Using a Body Fluid SampleAugust 2019December 2021Abandon2810NoNo
16531605Platform for Engineered Implantable Tissues and Organs and Methods of Making the SameAugust 2019July 2024Abandon5941NoNo
16465934MAGNETICALLY IMMOBILIZED METABOLIC ENZYMES AND COFACTOR SYSTEMSMay 2019October 2025Abandon6041YesNo
16422052ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711NoNo
16422023ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711YesNo
16422031ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711NoNo
16422045ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019November 2020Abandon1811NoNo
16422059ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711NoNo
16419904Process and Apparatus for Producing Mycelium BiomaterialMay 2019April 2024Abandon5950NoNo
16397159DETERMINATION OF A CONSTITUENT RELATED PROPERTY OF A MULTI-CONSTITUENT SAMPLEApril 2019June 2022Abandon3820YesNo
16382443METHOD FOR MANUFACTURING A STABLE AQUEOUS SOLUTION OF BETA-AMYLASE, AQUEOUS SOLUTION OBTAINED AND USES THEREOFApril 2019August 2022Abandon4041NoNo
16370109COMPOSITIONS FOR TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POST-MENOPAUSAL DYSPAREUNIA, AND/OR OOPHORECTOMIZED FEMALES AND TREATMENT METHODS THEREWITHMarch 2019February 2024Abandon5950YesNo
16332422Lin28a ACTIVATOR AND USE THEREFORMarch 2019November 2023Abandon5740YesNo
16351045METHOD FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASSMarch 2019June 2024Abandon6060YesNo
16277571Skin Care CompositionsFebruary 2019July 2022Abandon4130NoNo
16318684USE OF PROBIOTICS IN THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITISJanuary 2019November 2025Allow6071YesNo
16318037CHROMATIN PROTECTIVE THERAPEUTICS AND CHROMATIN HETEROGENEITYJanuary 2019December 2025Abandon6061YesNo
16237933COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASEJanuary 2019February 2022Abandon3740NoNo
16313359Cell enclosure device and use for sameDecember 2018July 2024Abandon6041NoNo
16216091AUTOMATED CELL COLLECTION AND SMEARINGDecember 2018February 2024Abandon6040NoNo
16209544COMPOSITION COMPRISING AN ACTIVATED MICROBIAL BIOMASSDecember 2018June 2022Abandon4241YesNo
16173536COMPOSITION USEFUL FOR THE PREPARATION OF A SUPPOSITORYOctober 2018February 2022Abandon3931NoNo
16172606ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFOctober 2018October 2020Abandon2410NoNo
16165712COMPOSITIONS CONTAINING EUGLENA GRACILIS FOR VIRAL PROTECTION AND RELATED METHODSOctober 2018September 2025Abandon6080YesNo
16094846Composition of proenzymes for cancer treatmentOctober 2018November 2024Abandon6061NoNo
16094384METHODS OF DEBRIDEMENT OF CHRONIC WOUNDSOctober 2018October 2024Abandon6061YesYes
16087028Device for Storing Blood and Method for Use ThereofSeptember 2018March 2023Abandon5401NoNo
16129870PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASESeptember 2018November 2024Abandon6091YesNo
16081975METHODS FOR EXPERIMENTAL EVOLUTION OF NATURAL AND SYNTHETIC MICROBESSeptember 2018May 2023Abandon5631NoNo
16074936COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTHAugust 2018November 2020Abandon2701NoNo
16071340BICOMPATIBLE PEPTIDEBIOCOMPATIBLE PEPTIDES FOR INHIBITION OF AGGREGATION OF B-AMYLOID PROTEINJuly 2018January 2025Abandon6031NoNo
15973903Compositions and Methods for Spine Fusion ProceduresMay 2018August 2021Abandon3920NoNo
15766627High-Throughput Platform for Bioprinting Tissue ModulesApril 2018November 2025Abandon6061YesNo
15946524New A-PRP Medical Device & Tissue Engineering Composition, Manufacturing Machines And ProcessApril 2018December 2023Abandon6061YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSS, NATALIE M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
9
(64.3%)
Examiner Reversed
5
(35.7%)
Reversal Percentile
56.9%
Higher than average

What This Means

With a 35.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
54
Allowed After Appeal Filing
8
(14.8%)
Not Allowed After Appeal Filing
46
(85.2%)
Filing Benefit Percentile
17.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MOSS, NATALIE M - Prosecution Strategy Guide

Executive Summary

Examiner MOSS, NATALIE M works in Art Unit 1653 and has examined 567 patent applications in our dataset. With an allowance rate of 32.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner MOSS, NATALIE M's allowance rate of 32.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MOSS, NATALIE M receive 2.71 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOSS, NATALIE M is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +27.6% benefit to allowance rate for applications examined by MOSS, NATALIE M. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 7.8% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 35.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 90.9% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.